Form 4: First Wave BioPharma President Acquires Shares in ImmunogenX Merger

Jack Syage, President and COO of First Wave BioPharma, acquired common stock and preferred stock through the company's merger with ImmunogenX.

Summary

• Jack Syage, President and COO of First Wave BioPharma, acquired 15,400 shares of common stock and 4,920.037 shares of Series G Non-Voting Convertible Preferred Stock on March 13, 2024.
• The acquisition was a result of First Wave BioPharma's merger with ImmunogenX.
• Syage received these shares in exchange for 352,000 shares of ImmunogenX common stock and 1,375,427 shares of ImmunogenX preferred stock.
• The preferred stock is held indirectly through the Jack A. Syage and Elizabeth T. Syage Revocable Trust.
• The preferred stock will automatically convert into common stock at a ratio of 1-for-1,000 upon stockholder approval, subject to beneficial ownership limitations.
• A conversion limitation prevents Syage from owning more than 19.9% of the outstanding common stock after conversion, which can be decreased to 4.9% with 61 days' notice.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports on a transaction related to a merger. The acquisition of shares by an executive could be seen as a positive sign, but the limitations on preferred stock conversion introduce some uncertainty.

Positives

• The acquisition of shares reflects Syage's increased stake in the combined entity following the merger.

Risks

• The conversion of preferred stock is subject to stockholder approval and beneficial ownership limitations, which could delay or limit the full conversion of Syage's preferred shares.

Future Outlook

The conversion of the preferred stock is contingent on future stockholder approval.

Industry Context

This announcement reflects insider activity related to a merger, which is a common occurrence in the biopharmaceutical industry as companies seek to expand their pipelines and capabilities.

Stakeholder Impact

• Shareholders will be impacted by the potential conversion of preferred stock into common stock, which could dilute existing shares.
• The merger itself impacts all stakeholders, including employees, customers, and suppliers.

Next Steps

• Stockholder approval for the conversion of the preferred stock is required.
• Syage may adjust the blocker percentage on the preferred stock conversion with 61 days' notice to the Issuer.

Key Dates

Keywords

First Wave BioPharma, ImmunogenX, merger, Jack Syage, common stock, preferred stock, beneficial ownership, conversion